Hoche Partners Pharma Holding SC 13D/AProcaps / Hoche Partners Pharma Holding ownership change

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934

(Amendment No. 10)

Procaps Group, S.A.

(Name of Issuer)

Ordinary Shares, nominal value of $0.01 per share

(Title of Class of Securities)

L7756P 102 (Ordinary Shares)

(CUSIP Number)

9 rue de Bitbourg, L-1273
Luxembourg
Grand Duchy of Luxembourg
R.C.S. Luxembourg: B253360
Tel : +356 7995-6138
(Address of Principal Executive Offices)

(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)

October 10, 2024

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box o.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7(b) for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Explanatory Note:

This Amendment No. 10 (“Amendment No. 10”) amends and supplements the statement on Schedule 13D of Hoche Partners Pharma Holding S.A. (the “Reporting Person” or “Hoche”) that was filed with the Securities and Exchange Commission (the “Commission”) on September 29, 2021 (the “Schedule 13D”), as amended by Amendment No. 1 to the Schedule 13D, filed with the Commission on January 12, 2024, as amended by Amendment No. 2 to the Schedule 13D, filed with the Commission on February 20, 2024, as amended by Amendment No. 3 to the Schedule 13D, filed with the Commission on July 22, 2024, as amended by Amendment No. 4 to the Schedule 13D, filed with the Commission on July 29, 2024, as amended by Amendment No. 5 to the Schedule 13D, filed with the Commission on August 8, 2024, as amended by Amendment No. 6 to the Schedule 13D, filed with the Commission on August 12, 2024, as amended by Amendment No. 7 to the Schedule 13D, filed with the Commission on August 23, 2024, as amended by Amendment No. 8 to the Schedule 13D, filed with the Commission on September 4, 2024, and as further amended by Amendment No. 9 to the Schedule 13D, filed with the Commission on September 19, 2024 with respect to the ordinary shares, nominal value of $0.01 per share, of Procaps Group, S.A., (the “Issuer” or “Procaps”). Capitalized terms used but not defined herein have the meanings given to such terms in the Schedule 13D. This Amendment No. 10 is being filed for the purpose of publicly disclosing certain important developments in connection with the Reporting Person’s investment in Procaps. Except as set forth herein, the Schedule 13D is unmodified.

Item 4 of the Schedule 13D is amended and supplemented as follows:

On October 10, 2024, Procaps filed a form 6-K to disclose certain interim results of its independent investigation. Amongst other consequences, (i) the Audit Committee of Procaps has concluded that Procaps' previously issued consolidated financial statements as of December 31, 2022 and 2021 and for each of the three years in the period ended December 31, 2022, issued on May 12, 2023, should no longer be relied upon; (ii) Procaps has to continue to expend resources towards concluding the independent investigation; and (iii) Procaps will no longer be able to meet the deadline of November 11, 2024 to file its 2023 annual report on Form 20-F for the fiscal year ended December 31, 2023.

The generic nature of the disclosure does little to highlight the obvious identities of the related parties involved. The lack of specificity of the exact nature of the illegal acts perpetuated at the behest of the controlling shareholders at the expense of Procaps and its minority shareholders is unacceptable and in our view disregards applicable securities laws. The form 6-K is again a facetious attempt to protect the identities and true nature of the extent of illegality perpetuated by the majority shareholders. A copy of the form 6-K is attached hereto as Exhibit 99.21.

Despite the above, Hoche remains committed to Procaps’ ability to create long-term value. In this regard, Hoche has sent a letter, which, amongst other thing, outlines Hoche’s strategies and conditions to improve Procaps’ financial situation. A copy of the letter is attached hereto as Exhibit 99.22.

Item 7 of the Schedule 13D is hereby amended by adding the following:

Exhibit 6-K —Form 6-K filed by Procaps Group, S.A. with the Securities and Exchange Commission on October 10, 2024.

Exhibit 99.22 — Letter from Hoche Partners Pharma Holding S.A. to the Board of Directors of Procaps Group, S.A. dated October 10, 2024

SIGNATURE

After reasonable inquiry and to the best of the Reporting Person’s knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: October 10, 2024&